Home » Stocks » KZIA

Kazia Therapeutics Limited (KZIA)

Stock Price: $9.71 USD 0.41 (4.41%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $9.07 -0.64 (-6.59%) Jul 23, 7:36 PM
Market Cap 129.32M
Revenue (ttm) 731,724
Net Income (ttm) -8.60M
Shares Out 12.96M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $9.71
Previous Close $9.30
Change ($) 0.41
Change (%) 4.41%
Day's Open 9.16
Day's Range 9.16 - 9.71
Day's Volume 17,889
52-Week Range 3.82 - 15.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness ...

4 days ago - PRNewsWire

SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two ...

3 weeks ago - PRNewsWire

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with t...

1 month ago - PRNewsWire

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigat...

1 month ago - PRNewsWire

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the firs...

1 month ago - Proactive Investors

SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually ...

1 month ago - PRNewsWire

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the company's bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey a...

1 month ago - Proactive Investors

Benjamin Graham, the pioneer of value investing, proposed to look for stocks that have a current ratio of more than 2 and more working capital than long-term debt.

Other stocks mentioned: CTHR, LPTX
2 months ago - GuruFocus

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey ac...

2 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it  "a vastly stronger and more substantial business", according t...

2 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial gro...

2 months ago - Proactive Investors

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m...

3 months ago - Accesswire

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of EVT...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European d...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) is in a trading halt pending an announcement in regard to a potential in-licensing transaction. In its application to the ASX for the halt, Kazia...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has secured an increased price target from A$2.25 to A$2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licensing...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Association...

3 months ago - Proactive Investors

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11...

3 months ago - Accesswire

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (HKSE:2096) to develop and commercialise Kazia's investigational new...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Greater Ch...

3 months ago - Benzinga

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has been granted a trading halt by the ASX pending the release of an announcement regarding a regional licensing transaction. The halt will be in...

3 months ago - Proactive Investors

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) chief executive officer and MD James Garner has highlighted the company's progress over the course of the year to date in its March newsletter,...

4 months ago - Proactive Investors

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cance...

Other stocks mentioned: OASM
4 months ago - Benzinga

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (STO:OASM) (OTCMKTS:OASMY) for Cantrixil (TRX-E-002-1), a cl...

Other stocks mentioned: OASM
4 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A$19.4 ...

5 months ago - Proactive Investors

Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

11 months ago - InvestorPlace

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital... [Read more...]

Industry
Biotechnology
IPO Date
Jan 6, 1999
Stock Exchange
NASDAQ
Ticker Symbol
KZIA
Full Company Profile

Financial Performance

In 2020, KZIA's revenue was 1.06 million, a decrease of -32.20% compared to the previous year's 1.57 million. Losses were -12.47 million, 21.4% more than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.02.

Price Target
$17.02
Analyst Consensus: Buy